| Literature DB >> 34069179 |
Maria Contaldo1, Alessandra Fusco2, Paola Stiuso3, Stefania Lama3, Antonietta Gerarda Gravina3, Annalisa Itro4, Alessandro Federico3, Angelo Itro1, Gianna Dipalma5, Francesco Inchingolo5, Rosario Serpico1, Giovanna Donnarumma2.
Abstract
Various bi-directional associations exist between oral health and gastro-intestinal diseases. The oral microbiome plays a role in the gastro-intestinal carcinogenesis and fusobacteria are the most investigated bacteria involved. This paper aims to review the current knowledge and report the preliminary data on salivary levels of Fusobacterium nucleatum, Porphyromonas gingivalis and Candida albicans in subjects with different gastro-intestinal conditions or pathologies, in order to determine any differences. The null hypothesis was "subjects with different gastro-intestinal diseases do not show significant differences in the composition of the oral microbiota". Twenty-one subjects undergoing esophagastroduodenoscopy or colonscopy were recruited. For each subject, a salivary sample was collected before the endoscopy procedure, immediately stored at -20 °C and subsequently used for genomic bacterial DNA extraction by real-time PCR. Low levels of F. nucleatum and P. gingivalis were peculiar in the oral microbiota in subjects affected by Helicobater pylori-negative chronic gastritis without cancerization and future studies will elucidate this association. The level of C. albicans did not statistically differ among groups. This preliminary study could be used in the future, following further investigation, as a non-invasive method for the search of gastrointestinal diseases and associated markers.Entities:
Keywords: Candida albicans; Fusobacterium nucleatum; Porphyromonas gingivalis; RT-PCR; chronic gastritis; microbiome; oral dysbiosis; oral microbiota; salivary markers
Year: 2021 PMID: 34069179 PMCID: PMC8156550 DOI: 10.3390/microorganisms9051064
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Figure 1The oral microbiota of a healthy mouth. On top, the percentage composition of phyla in the various niches (G1–G3) of the oral microbiota. G1, Group 1: keratinized gingiva, hard palate and the buccal mucosa; G2, Group 2, tongue, tonsils, throat and saliva; G3, Group 3, sub- and supra-gingival plaque. On the bottom, details on the percentage composition of phyla (left) and genera mainly present in salivary microbiota (right). The genera are represented in descending percentages, and color bars reflect the phyla they belong to. The organisms inhabiting saliva account for 99.9% of all bacteria in the oral cavity and are usually planktonic organisms.
Figure 2Oral bacteria and intestinal diseases. Oral bacteria can reach the intestines and stomach both through swallowing (a) and through the bloodstream (b). (c) At the level of the colon mucosa, they can compete with the local flora and establish intestinal dysbiosis. Pathogenic bacteria and their toxins alter the permeability of the basement membrane, perpetuate chronic inflammation and promote carcinogenesis. (d) Uncontrolled cell cycles reduced apoptotic efficiency and barrier damage results, thus leading to (e) chronic inflammatory diseases and the onset of cancers.
Oral bacteria associated with gastrointestinal diseases.
| G-i Diseases | Oral Bacteria/Fungi | Main Findings | Ref. |
|---|---|---|---|
| Gastritis | significantly higher in gastritis vs. healthy controls | [ | |
| decreased in gastritis patients vs. healthy control | [ | ||
| increased in gastritis patients vs. healthy control (mainly | [ | ||
| Gastric Precancerous lesions |
| positively associated with the precancerous cascade of gastritis | [ |
| increased in dental plaque of subjects with gastric precancerous lesions | [ | ||
| significantly associated with gastric precancerous lesions | [ | ||
|
| significantly inversely associated with gastric precancerous lesions | [ | |
| Oesophageal and Gastric Cancers | associated with higher risk of oesophageal cancers | [ | |
|
| higher in oesophageal cancer tissues than in oral cancer tissues | [ | |
|
| higher in oesophageal cancer tissues than matched normal mucosa; significantly associated with tumor stage and cancer-specific survival | [ | |
| potential role in alcohol-related | [ | ||
| significantly increased | [ | ||
| Inflammatory bowel diseases (IBDs) |
| significantly increased in IBDs | [ |
| increased in IBDs | [ | ||
|
| increases the mucosal permeability by affecting the tight junctions in IBDs | [ | |
|
| overrepresented in IBDs | [ | |
|
| isolated from the intestine more frequently in IBD patients | [ | |
| CRC | less abundant in CRC than healthy controls | [ | |
| tumor-associated bacteria | [ | ||
| more abundant in CRC than in healthy controls | [ | ||
|
| induces inflammatory | [ | |
| increases the CRC risk | [ | ||
|
| causes inflammation and promotes tissue degenerative processes | [ | |
|
| associated with CRC regional lymph node metastases | [ | |
| increased in CRC; induces colon cancer growth and progression | [ | ||
|
| can protect against CRC | [ | |
|
| sustains both the | [ |
Primer sequence and amplification conditions.
| Gene | Primers Sequence | Conditions | ProductSize (bp) |
|---|---|---|---|
|
| 5′-AGAGTTTGATCCTGGCTCAG-3′ | 5″ at 95 °C, 16″ at 55 °C, 8″ at 72 °C for 40 cycles | 407 |
|
| 5′-TGTAGATGACTGATGGTGAAAACC-3′ | 5″ at 95 °C, 5” at 52 °C, 4″ at 72 °C for 40 cycles | 198 |
|
| 5′-TTTATCAACTTGTCACACCAGA-3′ | 10″ at 95 °C, 10″ at 58 °C, 15″ at 72 °C for 30 cycles | 354 |
Datasets of the subjects enrolled.
| Id. Patient | Age (Years) | Sex | F.n. (ng/dL) | P.g. (pg/mL) | C.a. (pg/mL) | F.n. per Group (Mean ± SD) | P.g. per Group (Mean ± SD) | C.a. per Group * (Mean ± SD) | |
|---|---|---|---|---|---|---|---|---|---|
| CG Group | 2 | 49 | F | 0.10 | 0.03 | 156 | 1.10 ± 1.62 | 0.57 ± 1.17 | 39.36 ± 57.80 |
| 3 | 50 | F | 0.02 | 0.05 | 0 | ||||
| 6 | 68 | F | 2.40 | 0.04 | 0 | ||||
| 8 | 23 | F | 4.20 | 3.20 | 71.5 | ||||
| 10 | 47 | F | 0.00 | 0.15 | 12 | ||||
| 30 | 55 | F | 0.93 | 0.08 | 0 | ||||
| 44 | 46 | F | 0.08 | 0.44 | 36 | ||||
| Ex-CRC Group | 17 | 67 | M | 40.50 | 29.75 | 0 | 31.62 ± 34.40 | 7.78 ± 11.37 | 14.08 ± 15.76 |
| 22 | 58 | M | 3.85 | 1.4 | 0 | ||||
| 24 | 66 | F | 1.37 | 8.75 | 0 | ||||
| 27 | 63 | M | 95.00 | 0.01 | 32.5 | ||||
| 48 | 71 | F | 28.50 | 6.75 | 22.5 | ||||
| 50 | 62 | M | 20.50 | 0.000 | 29.50 | ||||
| CRC Group | 20 | 80 | M | 9.50 | 0.05 | 365.5 | 9.13 ± 6.03 | 2.88 ± 3.68 | 91.25 ± 182.50 |
| 29 | 63 | M | 1.50 | 0.03 | 0 | ||||
| 31 | 87 | F | 9.25 | 3.70 | 0 | ||||
| 39 | 63 | M | 16.25 | 7.75 | 0 | ||||
| Healthy control | 9 | 49 | F | 56.50 | 296.50 | 0 | 65.06 ± 14.92 | 110.19 ± 127.37 | 0 |
| 42 | 54 | F | 85.00 | 10.25 | 0 | ||||
| 45 | 51 | M | 67.50 | 78.00 | 0 | ||||
| 34 | 64 | F | 51.25 | 56.5 | 0 |
F.n. Fusobacterium nucleatum; P.g. Porphyromonas gingivalis; C.a. Candida albicans. * t-student test revealed no significant differences between any paired groups.
Correlations between groups: F. nucleatum levels.
| CG Group | Ex-CRC Group | CRC Group | Healthy Group | |
|---|---|---|---|---|
| Sample size | 7 | 6 | 4 | 4 |
| Mean F.n. values | 1.10 | 31.62 | 9.13 | 65.06 |
| Standard Deviation | 1.62 | 34.40 | 6.03 | 14.92 |
| t-student test | CG vs. ex-CRC * | |||
* Statistically significant at p < 0.05; n.s.: Not Significant.
Correlations between groups: P. gingivalis levels.
| CG Group | Ex-CRC Group | CRC Group | Healthy Control | |
|---|---|---|---|---|
| Sample size | 7 | 6 | 4 | 4 |
| Mean P.g. values | 0.57 | 7.78 | 2.88 | 110.19 |
| Standard Deviation | 1.17 | 11.37 | 3.68 | 127.37 |
| t-student test | CG vs. ex-CRC n.s. ( | |||
* Statistically significant at p < 0.05; n.s.: Not Significant.